Phase I study of irinotecan combined with carboplatin in previously untreated solid cancers

Clinical Cancer Research

Volumn 5, Issue 12, 1999, Pages 3963-3969

  Fukuda, Minoru ^a   Oka, Mikio ^a   Soda, Hiroshi ^a   Terashi, Kenji ^a   Kawabata, Shigeru ^a   Nakatomi, Katsumi ^a   Takatani, Hiroshi ^a   Tsurutani, Junji ^a   Tsukamoto, Kazuhiro ^a   Noguchi, Yuji ^a   Fukuda, Masaaki ^b   Kinoshita, Akitoshi ^c   Kohno, Shigeru ^a  

^a NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Nagasaki Atomic Bomb Hospital   (Japan)

^c Nagasaki Chuo National Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CARBOPLATIN; IRINOTECAN;

ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG TOLERANCE; FEMALE; HUMAN; LEUKOPENIA; LUNG CANCER; MALE; MALIGNANT NEOPLASTIC DISEASE; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CAMPTOTHECIN; CARBOPLATIN; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES;

EID: 0033378222     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Hsing, Y-H., Hertzberg, R., Hecht, S., and Liu, L. F. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem., 260; 14873-14878, 1985.
2. Hertzberg, R. P., Caranfa, M. J., and Hecht, S. M. On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex. Biochemistry, 28: 4629-4638, 1989.
3. Masuda, N., Kudoh, S., and Fukuoka, M. Irinotecan (CPT-11): pharmacology and clinical applications. Crit. Rev. Oncol. Hematol., 24: 3-26, 1996.
4. Fukuda, M., Nishio, K., Kanzawa, F., Ogasawara, H., Ishida, T., Arioka, H., Bojanowski, K., Oka, M., and Saijo, N. Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in a human small cell lung cancer cells. Cancer Res., 56: 789-793, 1996.
5. Kano, Y., Akutsu, M., Suzuki, K., and Yoshida, M. Effects of carboplatin in combination with other anticancer agents on human leukemia cell lines. Leuk. Res., 17: 113-119, 1993.
6. Kanzawa, F., Sugimoto, Y., Minato, K., Kasahara, K., Bungo, M., Nakagawa, K., Fujiwara, Y., Liu, L. F., and Saijo, N. Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non- small cell lung cancer: characterization and mechanism of resistance. Cancer Res., 50: 5919-5924, 1990.
7. Kudoh, S., Fujiwara, Y., Takada, Y., Yamamoto, H., Kinoshita, A., Ariyoshi, Y., Furuse, K., and Fukuoka, M. Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. J. Clin. Oncol., 16: 1068-1074, 1998.
8. Masuda, N., Fukuoka, M., Fujita, A., Kurita, Y., Tsuchiya, S., Nagao, K., Negoro, S., Nishikawa, H., Katakami, N., Nakagawa, K., and Niitani, H. Phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer. Br. J. Cancer, 78: 251-256, 1998.
9. Rose, W. C., and Schurig, J. E. Preclinical antitumor and toxicologic profile of carboplatin. Cancer Treat. Rev., 12: 1-19, 1985.
10. Lokich, J., and Anderson, N. Carboplatin versus cisplatin in solid tumors: an analysis of the literature. Ann. Oncol., 9: 13-21, 1998.
11. Calvert, A. H., Newell, D. R., Gumbrell, L. A., O'Reilly, S., Burnell, M., Boxall, F. E., Siddik, Z. H., Judson, I. R., Gore, M. E., and Wiltshaw, E. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J. Clin. Oncol., 7: 1748-1756, 1989.
12. Egorin, M. J., Van Echo, D. A., Olman, D. A., Whitacre, M. Y., Forrest, A., and Aisner, J. Prospective validation of a pharmacologically based dosing schema for cis-diamminedichloroplatinum (II) analogue diamminecyclobutanedicarboxylatoplatinum. Cancer Res., 45: 6502-6506, 1985.
13. Duffull, S. B., and Robinson, B. A. Clinical pharmacokinetics and dose optimisation of carboplatin. Clin. Pharmacokinet., 33: 161-183, 1997.
14. Chatelut, E., Canal, P., Brunner, V., Chevreau, C., Pujol, A., Boneu, A., Roche, H., Houin, G., and Bugat, R. Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J. Natl. Cancer Inst., 87: 573-580, 1995.
15. WHO. WHO Handbook for Reporting Results of Cancer Treatment. Geneva: WHO, 1979.
16. Mountain, C. F. A new international staging system for lung cancer. Chest, 89: 225S-233S, 1986.
17. LeRoy, A. F., Wehling, M. L., Sponseller, H. L., Friauf, W. S., Solomon, R. E., Dedrick, R. L., Litterst, C. L., Gram, T. E., Guarino, A. M., and Becker, D. A. Analysis of platinum in biological materials by flameless atomic absorption spectrophotometry. Biochem. Med., 18: 184-191, 1977.
18. Okamoto, H., Nagatomo, A., Kunitoh, H., Kunikane, H., and Watanabe, K. A Phase I clinical and pharmacologic study of a carboplatin and irinotecan regimen combined with recombinant human granulocyte-colony stimulating factor in the treatment of patients with advanced nonsmall cell lung carcinoma. Cancer (Phila.), 82: 2166-2172, 1998.
19. Jodrell, D. I., Egorin, M. J., Canetta, R. M., Langenberg, P., Goldbloom, E. P., Burroughs, J. N., Goodlow, J. L., Tan, S., and Wiltshaw, E. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J. Clin. Oncol., 10: 520-528, 1992.
20. Cockcroft, D. W., and Gault, M. H. Prediction of creatinine clearance from serum creatinine. Nephron, 16: 31-41, 1976.
21. Langer, C. J., Leighton, J. C., Comis, R. L., O'Dwyer, P. J., McAleer, C. A., Bonjo, C. A., Engstrom, P. F., Litwin, S., and Ozols, R. F. Paclitaxel and carboplatin in the treatment of advanced non-small-cell lung cancer: a Phase II toxicity, response, and survival analysis. J. Clin. Oncol., 13: 1860-1870, 1995.
22. van Warmerdam, L. J. C., Rodenhuis, S., ten Bokkel Huinink, W. W., Maes, R. A. A., and Beijnen, J. H. Evaluation of formulas using the serum creatinine level to calculate the optimal dosage of carboplatin. Cancer Chemother. Pharmacol., 37: 266-270, 1996.
23. Fukuoka, M., Furuse, K., Saijo, N., Nishiwaki, Y., Ikegami, H., Tamura, T., Shimoyama, M., and Suemasu, K. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimen in small-cell lung cancer. J. Natl. Cancer Inst., 83: 855-861, 1992.
24. Gridelli, C., Perrone, F., Ianniello, G. P., Brancaccio. L., Iaffaioli, R. V., Curcio, C., D'Aprile, M., Cioffi, R., Cigolari, S., Rossi, A., Palazzolo, G., Veltri, E., Pergola, M., De Placido, S., Gallo, C., Monfardini, S., and Bianco, A. R. Carboplatin plus vinorelbine, a new well-tolerated and active regimen for the treatment of extensive-stage small-cell lung cancer: a Phase II study. J. Clin. Oncol., 16: 1414-1419, 1998.
25. DeVore, R. F., Blanke, C. D., Denham, C. A., Hainsworth, J. D., Gralla, R. J., Koletsky, A. J., Savaraj, N., Vogel, C. L., Sarna, G. P., Brooks, D. J., Petit, R. G., Elfring, G. L., Schaaf, L. J., Hanover, C. K., and Miller, L. L. Phase II study of irinotecan (CPT-11) in patients with previously treated small-cell lung cancer (SCLC). Proc. Am. Soc. Clin. Oncol., 17: 451a, 1998.